Review

Na\textsuperscript{+}/K\textsuperscript{+}-ATPase Revisited: On Its Mechanism of Action, Role in Cancer, and Activity Modulation

Jiří Bejček \textsuperscript{1}, Vojtěch Spiwok \textsuperscript{1,\textcopyright}, Eva Kmoničková \textsuperscript{2} and Silvie Rimpelová \textsuperscript{1,3,*}

\textsuperscript{1} Department of Biochemistry and Microbiology, University of Chemistry and Technology Prague, Technická 3, 166 28 Prague 6, Czech Republic; jiri.bejcek@vscht.cz (J.B.); vojtech.spiwok@vscht.cz (V.S.)

\textsuperscript{2} Department of Pharmacology, Second Faculty of Medicine, Charles University, Plzeňská 311, 150 00 Prague, Czech Republic; eva.kmonickova@lfmotol.cuni.cz.

\textsuperscript{3} Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00 Pilsen, Czech Republic

\* Correspondence: silvie.rimpelova@vscht.cz; Tel.: +420-220-444-360

Abstract: Maintenance of Na\textsuperscript{+} and K\textsuperscript{+} gradients across the cell plasma membrane is an essential process for mammalian cell survival. An enzyme responsible for this process, sodium-potassium ATPase (NKA), has been currently extensively studied as a potential anticancer target, especially in lung cancer and glioblastoma. To date, many NKA inhibitors, mainly of natural origin from the family of cardiac steroids (CSs), have been reported and extensively studied. Interestingly, upon CS binding to NKA at nontoxic doses, the role of NKA as a receptor is activated and intracellular signaling is triggered, upon which cancer cell death occurs, which lies in the expression of different NKA isoforms than in healthy cells. Two major CSs, digoxin and digitoxin, originally used for the treatment of cardiac arrhythmias, are also being tested for another indication—cancer. Such drug repositioning has a big advantage in smooth approval processes. Besides this, novel CS derivatives with improved performance are being developed and evaluated in combination therapy. This article deals with the NKA structure, mechanism of action, activity modulation, and its most important inhibitors, some of which could serve not only as a powerful tool to combat cancer, but also help to decipher the so-far poorly understood NKA regulation.

Keywords: anticancer activity; cardiac glycosides; combination therapy; digoxin; digitoxin; digitoxigenin; Na\textsuperscript{+}/K\textsuperscript{+}-ATPase activity modulation; natural compounds; ouabain; sodium-potassium pump inhibitors

1. Introduction

Cancer is a highly variable disease in terms of its origin and biological characteristics of the affected tissues. There is a plethora of molecular targets, whose interactions with suitable molecules suppress the growth and spreading of neoplastic tissues. Each of these molecular targets has mostly a different mechanism of action.

The main role in cancer development is played by oncogenes that, when mutated, produce the corresponding proteins to a greater extent or in a form with increased or still “on” activity. Such a condition can be treated with inhibitors of the given proteins. One of such is imatinib mesylate (Gleevec\textsuperscript{TM}), the inhibitor of the Abelson tyrosine-protein kinase 1 (ABL1) used to treat chronic myeloid leukemia [1], inhibitors of the mammalian target of rapamycin (mTOR) [2], phosphatidylinositol 3-kinase (PI3K; [3]), or newly discovered pyrazolopyrimidine-based GTPase inhibitors of K-Ras (Kirsten sarcoma virus protein) [4].

However, there are many types of cancer and, therefore, in addition to these examples, a wide range of drugs and approaches acting by different mechanisms are used to treat cancer, discussed in detail in ref. [5,6]. These include, for example, anticancer chemotherapeutics such as commonly used cisplatin and oxaliplatin, which do not target only the tumor tissue and due to this non-selectivity cause many side effects. Recently, a big effort has been made to develop a therapy targeting specifically only tumor tissue, and thus,
generating minimum side-effects. One such potential targets for cancer therapy, which has attracted large attention lately, is the sodium-potassium ATPase (NKA).

NKA is an integral membrane protein localized in the cell plasma membrane of animal cells. NKA belongs to the enzyme class of translocases and it is an essential protein for maintaining ionic and osmotic balance in a eukaryotic cell. During one cycle, NKA exports three Na\(^+\) and imports two K\(^+\) ions while hydrolyzing one molecule of adenosine triphosphate (ATP). Therefore, NKA is also the key player in the transmission of nerve impulses throughout the body of a neuron \[7,8\]. Moreover, NKA is also responsible for the osmoregulation of Na\(^+\) and K\(^+\) ions in the hypertonic and hypotonic environment \[9–11\]. In addition to the transport function, NKA bears also a role of a receptor coupled with the Src family of nonreceptor tyrosine kinases, forming a functional complex for signal transduction \[12\]. This is the case when NKA is only partially inhibited and there is no significant disruption of the homeostasis of Na\(^+\) and K\(^+\) ions. Depending on the cell type, after activation by the respective ligand, NKA stimulates the proliferation of healthy cells \[13,14\] or, contrarily, inhibits the proliferation of tumor cells \[15,16\]. Due to the selective reduction of cancer cell proliferation, NKA currently represents a hot molecular target for anticancer therapy.

2. Na\(^+\)/K\(^+\)-ATPase Structure

According to the enzyme classification, NKA (Figure 1), being an integral membrane ion-transporting protein, belongs to the family of translocases (EC 7.2.2.13) utilizing the energy for ion transport from ATP hydrolysis. NKA occurs as a dimer composed of \(\alpha\) and \(\beta\) subunits, which have four and three tissue-specific isoforms, respectively \[17–21\].

![Figure 1. Structure of Na\(^+\)/K\(^+\)-ATPase (PDB, 3A3Y; [22]) with bound ouabain (green) in a molecular surface and cartoon view mode. Subunits are color-coded: Magenta (\(\alpha\) subunit), cyan (\(\beta\) subunit), and orange (FXYD subunit). The image was taken using PyMOL 2.3.3.](image)

The \(\alpha\) subunit is the catalytic part of the enzyme and, thus, executes all processes connected to the Na\(^+\) a K\(^+\) ion transport across the cell plasma membrane. It consists
of a transmembrane and a cytoplasmic part, the second of which can be further divided into an actuator (A), nucleotide-binding (N), and phosphorylation domain (P). The spatial arrangement of the transmembrane domain (M) consists of 10 \( \alpha \)-helices and is highly homologous with the three-dimensional structure of the transmembrane domain of another ATPase playing an important role in cancer research, the sarco-/endoplasmic reticular Ca\(^{2+}\)-ATPase (SERCA) [23]. In both structures, there are the same amino acid residues at the same positions in space except for L-Asp\(_{804}\) and L-Gln\(_{923}\), which are substituted with L-Asn\(_{804}\) and L-Glu\(_{923}\) in the SERCA protein [24].

The \( \beta \) subunit affects the affinity of Na\(^+\) and K\(^+\) ions to their binding sites [25] and augments the level of translation of the \( \alpha \) subunit [26]. The \( \beta \) subunit consists of an extracellular domain and one transmembrane helix, which interacts with transmembrane helices M\(_7\) and M\(_{10}\) of the \( \alpha \) subunit. The extracellular domain of the \( \beta \) subunit contains three glycosylation sites [27,28], in which the asparagine residues are glycosylated by oligosaccharides containing N-acetylglucosamine, mannose, and partially also galactose [29]. The glycosylation level of the \( \beta \) subunit affects its folding and subsequent translocation into the cell plasma membrane [30]. Moreover, the \( \beta \) subunit also protects the \( \alpha \) subunit from degradation, since NKA is translocated to the cell plasma membrane only as an \( \alpha/\beta \) heterodimeric complex [31,32]. The glycosylation level of the \( \beta \) subunit does not however have importance only for the aforementioned processes, but it also plays a significant role in other events such as cellular adhesion and polarization. It was reported that in polarized hepatocytes, NKA upon deglycosylation of the \( \beta \) subunit translocates into the apical instead of the basolateral membrane [33]. Targeting of NKA to the basolateral membrane is important because two adjacent cells are able to form tight junctions via \( \beta \) subunits interaction [34].

Even though that NKA is usually present in the form of a heterodimer of \( \alpha \) and \( \beta \) subunits, at some occasions, cells produce one extra subunit designated as FXYD. The FXYD subunit comprises in total seven isoforms, which are in all cases formed by one \( \alpha \)-helix. The FXYD subunit contains a conservative sequence, based on which this family of proteins was named. The FYD stands for L-Phe, L-Tyr, and L-Asp, respectively, \( X \) represents one of the following amino acids: L-Thr, L-Glu, L-Tyr, L-Phe, and L-His (Figure 2). Expression of the FXYD subunit is highly specific only for some tissues, mainly kidneys, heart, and muscles, summarized in Figure 3. Moreover, the expression of the FXYD subunit is also dependent on the salinity of the cell microenvironment [35]. In addition to that, a significantly increased expression of the isoform 3 of the FXYD subunit was reported for hepatocellular [36], colorectal [37], urinary bladder [38], breast carcinoma [39], and pancreatic cancer [40]. Therefore, this isoform could be conveniently utilized as a prognostic marker in the early onset of various cancer diseases.
Figure 2. Amino acid sequence alignment of seven human isoforms of FXYD subunit of Na⁺/K⁺-ATPase. A conservative FXYD sequence is highlighted in yellow. Other shared amino acids are in turquoise. An elongated N-terminus present in isoform 5 is depicted in italics. The sequences were taken from refs. [41–47]. * N-terminal extension of FXYD5 isoform.

Figure 3. The human proteome of individual Na+/K+-ATPase isoforms of α subunit (α-1, α-2, α-3, and α-4) β subunit (β-1, β-2, and β-3) and FXYD subunit (FXYD-1, FXYD-2, FXYD-3, and FXYD-6, data for FXYD-4, FXYD-5, FXYD-7 were not available). Data were taken from ProteomicsDB [48–58]. The color scale represents log10 normalized intensity-based absolute quantification (iBAQ) [59] for respective isoforms in a given tissue. The plots were prepared in R software, version 3.4.4.
Another role of the FXYD subunit is to stabilize NKA in the cell plasma membrane via interaction with phosphatidylserine [60]. An individual isoform of the FXYD subunit modulates the NKA activity in dependence on an affinity for Na\(^+\) and K\(^+\) ions to NKA, see summary in Table 1. Similar to the case of the \(\beta\) subunit, one isoform of the FXYD subunit (isoform 5) can also be glycosylated. However, contrary to the \(\beta\) subunit, glycosylation of the FXYD subunit reduces the level of cell adhesion by hampering transdimerization of the \(\beta\) subunits localized on adjacent cells [61].

Table 1. The affinity of individual Na\(^+\)/K\(^+\)-ATPase (NKA) isoforms of FXYD subunits for Na\(^+\) and K\(^+\) ions.

| Isoform | Affinity for Ions | References |
|---------|------------------|------------|
| 1 \(\text{a}\) | +/− | n.e. \(\text{b}\) | [62,63] |
| 2 | n.e. | + | [64] |
| 3 | − | − | [65] |
| 4 | + | − | [66] |
| 5 | + | − | [67] |
| 6 \(\text{c}\) | +/− | +/− | [68] |
| 7 \(\text{c}\) | +/− | n.e. | [69] |

\(\text{a}\) the affinity for Na\(^+\) depends on the level of NKA phosphorylation. \(\text{b}\) n.e.—not effective. \(\text{c}\) the affinity for Na\(^+\) and K\(^+\) depends also on the \(\alpha\) and \(\beta\) isoforms.

3. Catalytic Cycle of Na\(^+\)/K\(^+\)-ATPase

Based on the fact that NKA similarly to SERCA transports ions against the concentration gradient, both these enzymes utilize, for the Na\(^+\)/K\(^+\) and Ca\(^{2+}\), respectively, ion transport across the cell plasma membrane, energy that is supplied by a transfer of inorganic phosphate from the ATP molecule to L-Asp [70,71]. Both proteins interconvert between two conformational states called E1 and E2. The phosphorylation of L-Asp is characteristic for all types of these enzymes, based on which they previously belonged to the P-type ATPase class of enzymes (3.6.3.-).

The catalytic cycle of NKA is represented by the Post-Albers scheme, a model proposing how NKA transports the Na\(^+\) and K\(^+\) ions. During one cycle, three intracellular Na\(^+\) are transported into the extracellular space and two extracellular K\(^+\) in the opposite direction into the intracellular space via hydrolysis of one ATP molecule. The NKA catalytic cycle consists of the following steps:

- In the E\(_1\) state with bound ATP, the Na\(^+\) binding site in NKA is opened to the intracellular space and NKA has a high affinity for Na\(^+\) in this state.
- NKA phosphorylation occurs only when all Na\(^+\) binding sites are occupied since binding of the third Na\(^+\) ion causes a conformational change in the transmembrane domain, which is subsequently transferred to the nucleotide-binding domain [72].
- Then, after NKA phosphorylation, another conformational change takes place leading to the opening of the NKA cavity to the extracellular space, i.e., to the E\(_2\) state, and a release of Na\(^+\) [73].
- In the E\(_2\) state, NKA has a higher affinity for K\(^+\) ions. Upon their binding, NKA dephosphorylates and binds another molecule of ATP, which promotes the opening of the NKA cavity to the intracellular space, conversion to E\(_1\) state, and release of K\(^+\) ions [74,75].

By computational simulations, it was also shown that the NKA affinity to the corresponding ions is regulated in the E\(_1\) and E\(_2\) states by amino acid protonation (L-Asp\(_{804}\), L-Asp\(_{926}\), L-Asp\(_{808}\), L-Asp\(_{779}\), L-Asp\(_{954}\), L-Asp\(_{327}\), L-Asp\(_{779}\), L-Asp\(_{954}\)) in the active site of the enzyme [76]. Moreover, it was also found that the NKA catalytic cycle is affected by Mg\(^{2+}\) ions in the way that in the E\(_1\) state, the Mg\(^{2+}\) ions induce the cavity occlusion, followed by autophosphorylation and transition to the E\(_2\) state [77]. These data are further confirmed by the computational simulations by [78], who used molecular docking and simulations of molecular dynamics.
to show that Mg\(^{2+}\) facilitates NKA transition from the open to occluded conformation and subsequent autophosphorylation.

There are, in total, three binding sites (I, II, III) for Na\(^{+}\) and K\(^{+}\) ions localized in the transmembrane domain of NKA between the following helices: \(\alpha M_4\), \(\alpha M_5\), and \(\alpha M_6\) (I and II) and \(\alpha M_5\), \(\alpha M_6\), and \(\alpha M_6\) (III). The binding sites I and II are identical for K\(^{+}\) and Na\(^{+}\). However, the binding site III is highly selective only for Na\(^{+}\) ions and occurs only in the E\(_1\) state [76]. As aforementioned, the ion selectivity is reached by distinct protonation states in the individual phases of the catalytic cycle [76]. This fact was confirmed by [79], who also found that the protonation of \(L\)-Asp\(_{26}\) is driven by Cl\(^{-}\) ion binding, but the exact binding site has not been uncovered yet. Besides, \(L\)-Asp\(_{26}\) is an important amino acid residue necessary for the formation of the binding site III, since its deprotonation enables Na\(^{+}\) binding, and on the contrary, its protonation causes K\(^{+}\) transition into the binding sites I and II [79].

The catalytic cycle occurs at the physiological Na\(^{+}\) and K\(^{+}\) ion concentrations; however, interestingly, it was also reported that at low Na\(^{+}\) and K\(^{+}\) concentrations, NKA can also transport H\(^{+}\) ions. In such a case, the NKA activity highly depends on the pH value, growing with decreasing pH. During this catalytic cycle, two H\(^{+}\) ions are transported to the extracellular space and then two H\(^{+}\) ions inside the cell upon hydrolysis of one ATP molecule [80].

### 4. Na\(^{+}/K^{+}\)-ATPase Functions and Anticancer Potential of Cardiac Steroids

As mentioned above, the main role of NKA is to maintain the homeostasis of Na\(^{+}\) and K\(^{+}\) ion concentrations, by which it significantly contributes to osmoregulation and maintenance of the resting membrane potential. Besides, NKA function is associated with cellular signaling resulting from its interaction with cardiac steroids (CSs). CSs are substances of a steroid character naturally occurring in sundry plants, mainly from the genus *Digitalis*, and organisms. However, there are also endogenous CSs, such as ouabain (1; Figure 4) and dihydroouabain [81]. The endogenous CSs are probably the reason that NKA contains in its structure the binding site for these compounds, which our body produces at picomolar to low nanomolar concentrations. At these low concentrations, NKA is not inhibited, but on the contrary, its activity is stimulated or NKA can also act as a signal transducer. Stimulation of NKA activity was observed in cardiac myocytes derived from humans, canines, and guinea pigs. The NKA activity stimulation was detected in an isoform-specific manner, which means that the most sensitive to this stimulation was \(\alpha_2\) isoform [82]. Kundmiri et al. [83,84] have associated low concentrations of compound 1 with activation of NKA signaling cascades and consequently increased proliferation of opossum kidney cells as well as with stimulation of NKA ion transport. Therefore, this mechanism could be the way that the body copes with low sodium levels. Indeed, elevated amounts of compound 1 in plasma have been found in patients with low sodium [85]. The ability of compound 1 to cause organ hypertrophy and to increase cell proliferation has been reported by many authors so far, and it is probably the reason that compound 1 is often found in the plasma of patients with increased blood pressure [86,87].

![Chemical structures of ouabain (1)](image-url)
It has long been known that a certain part of NKA is complexed with the non-receptor tyrosine kinase (Src kinase, SrcK), caveolin, and the epidermal growth factor receptor, which altogether form a signalosome in the caveolae of the cytoplasmic membrane. In such a case, the NKA lacks its transport function and, conversely, acquires a signaling function \[88,89\]. SrcK is inactive in this complex, however after the interaction of CSs with NKA, dissociation of SrcK and NKA occurs. SrcK subsequently phosphorylates the epidermal growth factor receptor \[90,91\] and a subsequent cascade of events results in stimulation of cell proliferation. This mechanism was demonstrated in a study in which SrcK activation occurred after stimulation of cells derived from autosomal-dominant polycystic kidney disease with ouabain (Figure 4)—a major representative of CSs broadly used in experimental pharmacology \[92\]. The same effect was also observed in venous endothelial cells \[95\]. Furthermore, in the case of reduced NKA production in prostate, breast, and kidney tumors and subsequent metastases, there was an increase in SrcK activity followed by induction of cell proliferation \[94\]. Thus, to induce cell proliferation by SrcK, it must not be in a complex with NKA, and this condition can be achieved by the aforementioned ways. This statement is also supported by the fact that treatment of cells with a synthetic peptide (pNaKtide) mimicking NKA reduces SrcK activity \[95\]. Newly, an effect of pNaKtide on the regulation of aging \[96\], lipid accumulation, and with it associated obesity \[97\], as well as suppression of steatohepatitis and atherosclerosis in mice, has also been recently discovered \[98\]. All these phenomena have been observed in connection with the production of reactive oxygen species (ROS), which are also associated with SrcK activation. ROS play a role in signal transduction from NKA to SrcK and, thus, it probably forms a self-amplifying loop. The importance of ROS for SrcK activation has been also demonstrated by Wang et al. \[99\], who reported successful SrcK activation in porcine kidney cells with hydrogen peroxide. An elevated amount of ROS causes NKA carbonylation, which possibly regulates signaling by modifying the interaction of NKA with signalosome partners \[100\]. Carbonylation was observed after stimulation of porcine kidney cells by compound 1. Contrary to that, decarbonylation of the A domain of NKA occurred after the removal of compound 1 from the cell culture medium \[101\]. The interaction of NKA with Src kinase is mediated by two domains in both proteins. The first one is localized in the A domain of NKA and the SH2 domain of Src, and the second one is in the N domain of NKA and the kinase domain of Src \[102\]. The mutual interaction of NKA with Src is also likely to be dependent on the NKA isoform. It was found that isoform α-2 of NKA cannot bind to Src unless its sequence does not contain residues responsible for the interaction of Src with isoform α-1 \[102\].

Furthermore, in the presence of compound 1, the NKA signalosome activates phospholipase C, which then cleaves phosphatidylinositol 4,5-bisphosphate to inositol 1,4,5-triphosphate (IP_3). IP_3 interacts with the IP_3 receptor and this interaction results in oscillations of cytosolic Ca^{2+} \[103,104\]. These oscillations subsequently induce the synthesis of the antiapoptotic subunit p65 of nuclear factor kappa B and antiapoptotic factor B-cell lymphoma-extra-large (Bcl-xL) \[105\] and the activation of calmodulin-dependent kinase 2G, which inactivates the proapoptotic protein Bcl2-associated agonist of cell death (BAD) \[106\]. All of these effects were observed in noncancerous cells derived from renal tissue.

Another mechanism of NKA signal transduction that is independent of SrcK is the activation of PI3K, which suppresses cell motility by actin restructuralization and promotes cell adhesion with βS NKA \[107,108\]. However, some authors also reported that the processes associated with cell adhesion and the formation of tight and gap junctions are also linked to NKA/SrcK signaling \[109\], or even that this pathway promotes cell migration and healing \[110\]. This means that this mechanism has not been reliably elucidated yet.

Another phenomenon, which has also not been reliably explained, yet is the mechanism by which NKA contributes to its anticancer activity. From the facts described above, in particular the induction of cell proliferation and antiapoptotic action, at first glance, it might seem that NKA may not be a suitable target for tumor therapy, in which the antiproliferative effects and proapoptotic action are highly desired. Originally, it was
described that CSs exhibit proapoptotic effects via NKA inhibition at orders of magnitude higher concentrations, at which a positive inotropic effect in the heart occurs [111]. This results in the long-term increase in intracellular concentration of Ca\(^{2+}\), which leads to apoptosis. However, this mechanism occurring at higher CS concentrations is not selective for cancer cells and proceeds in both cancerous and noncancerous cells [112,113]. Further in-depth studies provided new data about the different effects of CSs in normal and cancer cells. Very low concentrations of CSs induce cell proliferation in noncancerous cells caused by SrcK activation but apoptosis is induced in cancer cell lines [15]. Interestingly, anticancerous effects via the activation of signal transduction occur at very low concentrations (picomolar to low nanomolar) of several tested CSs, which are below the concentrations causing NKA inhibition [15]. Kometiani et al. reported cell cycle arrest of breast cancer cells after their treatment with compound 1 (concentrations were far below the half-maximal inhibitory concentration [IC\(_{50}\)], which was caused by activation of the SrcK pathway and subsequently increased levels of the cell cycle inhibitor p21\(^{cip1}\) (cyclin-dependent kinase inhibitor 1) [114]. In a different study, digoxin (2, Figure 5) exhibited a cytotoxic effect in several cell lines derived from lung tumors; however, this activity was caused by SrcK and PI3K inhibition, not by SrcK activation [115]. Further, in another study, compound 1 was able to cause SrcK inhibition in human cells derived from lung adenocarcinoma (A549), which led to downregulation of focal adhesion kinase (FAK), underlining the fact that interaction of CSs with NKA in cancer cells leads to different outcomes than in non-transformed cells [116]. FAK plays role in regulating cell motility as was in the work of Pongrakhananon et al. [117], where compound 1 reduced tumor cell motility of lung cancer cells by reducing the activity of FAK, which could lead to hampering of metastatic potential of cancer cells. Reduced activity of FAK and subsequently reduced cell motility could not only reduce metastasis but could also lead to inhibition of angiogenesis as was reported by several researchers [118–120]. This is supported by the work of Trenti et al. [121], who reported concentration-dependent inhibition of migration of HUVEC cells after treatment with compound 1. Angiogenesis is also closely related to hypoxia-inducible factors, a group of transcription factors that regulate the expression of angiogenic genes [122]. One of those factors is hypoxia-inducible factor 1 alpha (HIF-1\(\alpha\)), which was shown to regulate the expression of vascular endothelial growth factor (VEGF) and angiopoietin/Tie-2 system [123]. It was discovered that protein synthesis of HIF-1\(\alpha\) and its downstream target VEGF is inhibited by compounds 1 and digitoxin (3, Figure 5) leading to reduced invasive capabilities of affected cells and consequently to the slower formation of new blood vessels [124–126]. Antiproliferative effects of compounds 1 and 2 used for the treatment of cells derived from colorectal carcinomas were also demonstrated in connection with NKA and volume-regulated anion channels (VRAC), since after stimulation of NKA with CSs, VRAC is opened, cell volume is reduced, the consequence of which cell proliferation is inhibited. It is also worth mentioning that these effects were not observed in a noncancerous cell line of human fibroblasts (Hs68) [127]. Therefore, it is clear that the interaction of CSs with NKA and the subsequent activation of signaling cascades has an antitumor effect, but the mechanism of action differs not only between noncancerous vs. cancerous cells but also among various cancer types. Furthermore, NKA is not only associated with the aforementioned signal cascades, but also with many other cellular processes. Some of these associated processes can be predicted by databases such as the STITCH 5.0 database, and the interactions are depicted in Figure 6. Taken together, the anticancer mechanism of CSs is dependent on their concentration. At higher concentrations (above IC\(_{50}\)), they inhibit NKA by which they disrupt the ion homeostasis leading to apoptosis. On the other hand, at concentrations far below IC\(_{50}\), CSs activate several signaling pathways that are involved in their anticancer action. These actions also depend on the cancer type and include the aforementioned processes such as retention of the cell cycle by p21\(^{cip1}\), activation or inhibition of SrcK, regulation of cell volume by VRAC, and inhibition of cell motility, and angiogenesis.
5. Regulation of Na+/K+-ATPase Activity

Figure 5. Chemical structures of digoxin (2) and digitoxin (3).

Figure 6. Predicted functional association network for sodium-potassium ATPase (NKA) isoforms (ATP1B4, ATP1B2, ATP1B3, ATP1A2, ATP1B1, ATP1A4, ATP1A3, ATP1A1) created by STRING 11.0 database [128]. The nodes represent gene products depicted in an evidence view mode. The type of the lines indicates knowledge or prediction of the protein-protein associations: Turquoise = from curated databases, pink = experimentally determined, green = gene neighborhood, red = gene fusions, blue = gene co-occurrence, yellow = text mining, black = co-expression, violet = protein homology. The NKA isoforms association network was generated for *Homo sapiens* species with the confidence score set to 0.700 with a maximum of 50 interactions. Small and large nodes represent proteins with unknown and known or predicted 3D structures, respectively. A description of the listed gene products is in Supplementary Information Table S1.
5. Regulation of Na\(^+\)/K\(^+\)-ATPase Activity

5.1. Exogenous NKA Modulators

The most well-known NKA effectors modulating its activity are CSs, the chemical structure of which contains a steroid skeleton substituted with a lactone and saccharide moiety at the positions C-17 and C-3, respectively. As mentioned in Chapter 4, CSs can modulate NKA activity and are among the main exogenous effectors of this protein. The binding site for CSs is located in the M domain among the M\(_{1}\)–M\(_{6}\) helices with the highest affinity in the P-E\(_{2}\) state, i.e., with released Na\(^+\) and not yet bound K\(^+\) [129]. The cavity, into which the steroid skeleton of CSs is bound, consists of a hydrophobic surface comprising amino acids L-Ile\(_{315}\), L-Phe\(_{316}\), L-Gly\(_{319}\) (M\(_{4}\)), L-Phe\(_{783}\), L-Phe\(_{786}\) (M\(_{5}\)), and L-Leu\(_{793}\) (loop M\(_{5–6}\)) and hydrophilic surface composed of amino acids L-Gln\(_{111}\) (M\(_{1}\)), L-Glu\(_{117}\), L-Asp\(_{121}\), L-Asn\(_{122}\) (M\(_{2}\)), and L-Thr\(_{797}\) (M\(_{6}\)) [130]. Of the aforementioned, amino acid residues L-Gln\(_{111}\), L-Asn\(_{122}\), and L-Thr\(_{797}\) are the most important for CS binding, as their substitution significantly reduces the sensitivity of NKA to CSs, as evidenced by numerous mutagenesis studies [131–134].

Dominant CS representatives are compounds 1, 2, and 3. Besides NKA, these compounds can interact with a large variety of targets, some of which are depicted in Figure 7. Compounds 1, 2, and 3, are currently the most widely used to study the interaction of CSs with NKA, as well as for the development of novel inhibitors. The most important element of the CS structure is the steroid core motif substituted by a lactone at C-17 and by a carbohydrate at C-3. It is exactly the structure of these three parts that are used in the development of novel NKA inhibitors or for the interaction studies.

![Figure 7](image-url)
ouabain created by STITCH 5.0 database [135]. The nodes represent gene products depicted in a molecular action view. The type of the lines indicates the predicted mode of action: Green = activation, blue = binding, turquoise = phenotype, black = reaction, red = inhibition, dark blue = catalysis, pink = posttranslational modification, yellow = transcriptional regulation, a line with an arrowhead = positive, a line with a vertical bar = negative, a line with a filled circle = unspecified interaction. The cardiac steroid association network was generated according to the known and predicted interactions for Homo sapiens with the confidence score set to 0.700 with a maximum of 50 interactions. Small and large nodes represent proteins with unknown and known or predicted 3D structures, respectively. A description of the listed gene products is in Supplementary Information Table S2.

Appropriate distribution of hydroxyl groups on the steroid skeleton of CSs is important for their binding to NKA. The NKA binding pocket for CSs consists of a polar and non-polar part. Correspondingly, the structure of the CS steroid skeleton can be divided into polar and nonpolar surfaces. This fact is most evident in compound 1, which, in addition to the conservative hydroxyl group at C-14, also contains hydroxyl groups at C-1, C-5, C-11, and C-19 positions and, thus, exhibits a greater in vitro NKA inhibition in comparison to compounds 2 and 3 [136]. The importance of polar interactions is evidenced by the work of Magpusao et al. [137], who blocked the hydroxyl groups of compound 1 at C-1 and C-19 positions using an acetonide group yielding a derivative 4 (Figure 8), the IC\textsubscript{50} of which increased almost 120-fold in comparison to compound 1 in NKA activity assay.

![Chemical structure of compound 4.](image)

Another structural motif also significantly involved in the CS binding to NKA is the lactone at the C-17 position. Its derivatization usually leads to a reduction in the NKA inhibitory effects of the resulting derivative, both in the case of double bond saturation and cycle opening [138,139] as well as by the introduction of a benzylidene group at the C-21 position [140,141]. However, in some cases, this modification resulted in a change in the CS affinity for the individual NKA isoforms [142]. This fact was also confirmed by the work of [143], who reported on specific inhibition of the α-4 isofrom of NKA caused by a newly prepared derivative of compound 1, in which the lactone group was replaced by a benzotriazole moiety, and whose IC\textsubscript{50} on NKA (α-4 isofrom) was three orders of magnitude lower than that for compound 1.

Glycosylation of the hydroxyl at the C-3 position also alters the strength of CS interaction with NKA and its resulting inhibitory properties. Iyer et al. [144] investigated the effect of O-glycoside substitution for MeON-neoglycoside in the structure of compound 3 (Figure 5) as well as the effect of the glycosylation level of this CS on the NKA inhibitory potential. In both groups (O-glycosides and MeON-neoglycosides), the NKA inhibitory potency of compound 3 derivatives increases with the descending level of glycosylation. Furthermore, compared to O-glycosylated derivatives of compound 3, MeON-neoglycosidated compounds exhibited reduced cytotoxicity in vitro. A similar effect of CS glycosylation level on NKA inhibition was also reported by Elbaz et al. [145].
though there is a correlation of increasing inhibitory activity of CSs towards NKA with a decreasing level of CS glycosylation, this does not apply to CS aglycones. It has been reported that an aglycone of a glycosylated form of a CS exhibits reduced NKA inhibition even when compared to triglycosylated forms of CSs [136]. The glycosylated forms of compounds 1, 2, and 3 also exhibit different affinities for the individual NKA isoforms, whereas the aglycones themselves do not [146]. Of the aforementioned NKA inhibitors, only compound 2 is currently under clinical evaluation as a potential drug for cancer treatment. Clinical trials including compound 2 are performed at phase I and II of clinical testing for therapy of various types of cancer (prostate, breast, pancreas, head and neck, lung, etc.) are summarized in Table 2. Not surprisingly, compound 2 is a good candidate for repurposing as a potential anticancer compound. Long-term experience of clinicians with the administration of compound 2 in cardiac diseases and collecting clinical data can overcome pharmacokinetics weaknesses of this compound, mainly the narrow therapeutic window. Moreover, results of research focusing on its antitumor effects show that low nanomolar concentrations are needed to affect molecular structures in cancer cells.

However, it seems that the biology of individual types of tumors (solid or others) offers different molecular pathways and targets for anticancer intervention of many CSs. Compounds 1–3, and also other less known CSs isolated from plants, were intensively studied in the two past decades to show the anticancer mechanism in detail. Based on many individual experiments, new findings have emerged, i.e., the inhibition of NKA is transduced and continues by changes in intracellular signaling pathways. Next to Src kinase signaling described above, p38-mitogen-activated protein kinase (MAPK) cascade, PI3K/protein kinase B (Akt)/mTOR pathway, and p21, or cholesterol homeostasis are also linked to α and β subunits of NKA. Specifically, for compound 2, we can conclude that inhibition of Src signaling cascade, inhibition of hypoxia-inducible factor-1 alpha (HIF-1α) synthesis, and inhibition of androgen-dependent/independent mechanisms are the main modes of CS action for non-small-cell lung cancer, hepatoma Hep3B cells, and prostate cancer cells, respectively [147]. In clinical trials currently being performed [148], the investigation of compound 2 in the treatment of predominantly solid tumors (prostate, breast, pancreas, head and neck, lung, and melanoma) continues. Some clinical trials examine the efficacy of monotherapy of compound 2, as has been designed for the treatment of Kaposi’s sarcoma. HIF-1α is the major regulator of tumor growth in this type of sarcoma. Other trials are related to combinatory therapy with other anticancer drugs as a currently recruiting clinical trial [149] in patients with resectable pancreatic cancer. Other studies are focused on pharmacokinetic parameters and interactions in combinatory therapy of malignant melanoma [150].

Table 2. Clinical trials of digoxin (2) for cancer treatment; the data were taken from [151].

| Clinical Trial Identifier | Study Title | Condition or Disease | First Posted | Status | Phase | Intervention/Treatment |
|--------------------------|-------------|----------------------|--------------|--------|-------|-----------------------|
| NCT02906800 | Potentiation of cisplatin-based chemotherapy by digoxin in advanced unresectable head and neck cancer patients | Head and neck cancer | 20 September 2016 | Unknown | I, II | Digoxin |
| NCT04094519 | A study to evaluate the effect of multiple doses of enzalutamide on the pharmacokinetics of substrates of P-glycoprotein (digoxin) and breast cancer resistant protein (rosuvastatin) in male subjects with prostate cancer | Prostate cancer | 19 September 2019 | Active, not recruiting | I | Enzalutamide, enzalutamide placebo, digoxin, rosuvastatin |
| NCT01763931 | DIG-HIF-1 pharmacodynamic trial in newly diagnosed operable breast cancer | Breast cancer | 9 January 2013 | Completed | II | Digoxin |
| NCT01162135 | Digoxin for recurrent prostate cancer | Prostate cancer | 14 July 2010 | Completed | II | Digoxin |
| Clinical Trial Identifier | Study Title | Condition or Disease | First Posted | Status | Phase | Intervention/Treatment |
|--------------------------|-------------|----------------------|--------------|--------|-------|------------------------|
| NCT01887288              | Capecitabine with digoxin for metastatic breast cancer | Metastatic breast cancer | 26 June 2013 | Terminated | II | Capetabine, digoxin |
| NCT00650910              | Study to examine the effects of lapatinib on the pharmacokinetics of digoxin in subjects w/ErB2 positive breast cancer | Neoplasm, breast | 2 April 2008 | Completed | I | Lapatinib, digoxin |
| NCT03889795              | Phase IB metformin, digoxin, simvastatin in solid tumors | Advanced pancreatic cancer, advanced solid tumor | 26 March 2019 | Recruiting | I | Metformin, simvastatin, digoxin |
| NCT03928210              | Digoxin induced dissolution of CTC clusters | Breast cancer, circulating tumor cells (CTCs) | 26 April 2019 | Not yet recruiting | I | Digoxin |
| NCT04141995              | FOLFIRINOX with digoxin in patients with resectable pancreatic cancer | Pancreas cancer, adenocarcinoma of the pancreas | 26 October 2019 | Not yet recruiting | II | Digoxin, 5-fluorouracil, calcium leucovorin, irinotecan, oxaliplatin |
| NCT02106845              | Effect of regorafenib on digoxin and rosuvastatin in patients with advanced solid malignant tumors | Neoplasms | 8 April 2014 | Completed | I | Digoxin, rosuvastatin, regorafenib |
| NCT04322552              | A pharmacokinetic interaction study between apatinib mesylate and transporter Pgp substrate digoxin in advanced solid tumor subjects | Advanced solid tumor | 26 March 2020 | Recruiting | I | Apatinib mesylate, digoxin |
| NCT01517399              | Drug-drug interaction study of tivantinib (ARQ 197) with omeprazole, S-warfarin, caffeine, midazolam, and digoxin in cancer subjects | Solid tumors | 25 January 2012 | Completed | I | Tivantinib, omeprazole, s-warfarin, caffeine, vitamin K (dietary supplement), digoxin, midazolam |
| NCT02626234              | A drug-drug interaction (DDI) study to assess the effect of INC280 on the pharmacokinetics of digoxin and rosuvastatin in patients with cMET-dysregulated advanced solid tumors | cMET-dysregulated Advanced Solid Tumors | 10 December 2015 | Completed | I | INC280, digoxin, rosuvastatin |
| NCT00281021              | Second line erlotinib (Tarceva) plus eigoxin in non-small cell lung cancer | Carcinoma, non-small cell lung | 24 January 2006 | Terminated | II | Erlotinib, digoxin |
| NCT01765569              | A pharmacokinetic study to investigate the effect of vemurafenib on Digoxin in Patients With BRAFV600 mutation-positive Metastatic Melanoma | Malignant melanoma, neoplasms | 10 January 2013 | Completed | I | Digoxin, vemurafenib |
| NCT02740712              | Pharmacokinetic drug-drug interaction study of rucaparib (DDI) | Neoplasms | 15 April 2016 | Completed | I | Caffeine, warfarin, omeprazole, midazolam, digoxin, vitamin K, rucaparib |
| NCT02212639              | Phase II multicentric study of digoxin per os in classic or endemic Kaposis sarcoma (KADIG 01) | Classic and endemic Kaposis sarcoma, lymphangio proliferations | 8 August 2014 | Unknown | II | Digoxin |
Table 2. Cont.

| Clinical Trial Identifier | Study Title                                                                 | Condition or Disease                      | First Posted       | Status            | Phase | Intervention/Treatment |
|---------------------------|------------------------------------------------------------------------------|-------------------------------------------|--------------------|-------------------|-------|------------------------|
| NCT037260366              | A study of perpetrator drug interactions of enasidenib in AML patients       | Leukemia, myeloid, acute                  | 25 October 2018    | Not yet recruiting | I     | Caffeine, dex-         |
|                           |                                                                              |                                           |                    |                   |       | tromethorphan,         |
|                           |                                                                              |                                           |                    |                   |       | flurbiprofen,          |
|                           |                                                                              |                                           |                    |                   |       | midazolam,             |
|                           |                                                                              |                                           |                    |                   |       | omeprazole,            |
|                           |                                                                              |                                           |                    |                   |       | digoxin, rosuvastatin, |
|                           |                                                                              |                                           |                    |                   |       | pioglitazone           |
| NCT03684772               | Topical ionic contra-viral therapy in actinic keratosis                      | Actinic keratosis                         | 26 September 2018  | Recruiting        | II    | ICVT topical gel,      |
|                           |                                                                              |                                           |                    |                   |       | furosemide topical,    |
|                           |                                                                              |                                           |                    |                   |       | digoxin topical gel,    |
|                           |                                                                              |                                           |                    |                   |       | vehicle topical gel    |
| NCT02138292               | A phase 1B clinical trial of trametinib plus digoxin in patients with       | Melanoma                                  | 14 May 2014        | Completed         | I     | Trametinib,            |
|                           | unresectable or metastatic BRAF wild-type melanoma                           |                                           |                    |                   |       | digoxin                |
| NCT02915666               | A clinical trial of patients with melanoma                                   | Melanoma                                  | 27 September 2016  | Withdrawn         | I     | Digoxin combination,   |
|                           |                                                                              |                                           |                    |                   |       | dabrafenib, trametinib |
| NCT02732275               | DS-3201b in participants with lymphomas                                      | Lymphoma, malignant, non-Hodgkin lymphoma| 8 April 2016       | Recruiting        | I     | DS-3201b, midazolam,   |
|                           |                                                                              |                                           |                    |                   |       | digoxin                |
| NCT02333643               | A phase 2 efficacy study of CLS003 ICVT in subjects with cutaneous warts    | Cutaneous warts                           | 7 January 2015     | Completed         | II    | CLS003, furosemide,    |
|                           |                                                                              |                                           |                    |                   |       | digoxin, vehicle       |
|                           |                                                                              |                                           |                    |                   |       | topical                |

Apart from compound 1, 2, and 3, other substances belonging to the group of CSs are also mentioned in the literature as NKA inhibitors, e.g., gitoxin (5), evomonoside (6), bufalin (7), cinobufagin (8), and gamabufotalin (9) (Figure 9) [136,152]. Although CSs are the best-known NKA inhibitors, other groups of compounds with the ability to inhibit this protein have been discovered lately. These compounds are characterized by condensed aromatic or saturated rings, so we may speculate similar pharmacophore as for CSs in NKA inhibition. These compounds are sesquiterpenes (10–13, Figure 9) isolated from *Thujopsis dolabrata*. Some compounds from this group exhibit anticancer and antimicrobial activity [153], and, more recently, the ability to also inhibit NKA was discovered. Their structure–activity relationship has not yet been fully elucidated. However, the hydroxymethylene group at the C-11 position of compound 10 is important for higher NKA inhibitory activity. When this group is replaced by an aldehyde group, the NKA inhibitory activity of the resulting derivative, i.e., compound 11, decreases almost four times. Moreover, the substitution of the hydroxymethylene group (compound 12) with a methyl group leads to loss of NKA inhibitory activity (compound 13) [154].
Furthermore, panaxatriol (14, Figure 9) and its derivatives (15, 16, Figure 9), belonging to the group of triterpenes, are similar to the structure of CSs since they share a steroid skeleton. The inhibitory potency of compound 14 can be further increased by the introduction of a benzyl ether moiety (compound 15, a three-time increase) and also by opening the A ring (compound 16, a four-time increase) [155].

Istaroxime (17, Figure 9) is a synthetic derivative derived from 5α,14α-androstane with the ability to inhibit NKA [156]. Istaroxime is also known for its anticancer effect [157]. Later, other derivatives based on the structure of compound 17 with enhanced NKA inhibitory activity were developed. Two of these derivatives (18, 19, Figure 9) exhibited
significantly higher inhibitory activity compared to compound 17. This was achieved by replacement of linear 2-aminoethyl oxime at the C-3 position by (3R)-3-pyrrolidinoxyiminooxime chain and by introducing an oxime moiety in the C-6 position [158]. Another group of NKA inhibitors comprises substances derived from xanthone (compounds 20, 21, Figure 9), the potency of which to inhibit NKA depends on the number and position of hydroxyl groups; it increases with the higher hydroxyl group number. However, methylation of hydroxyl groups, on the other hand, leads to a reduction of their NKA inhibitory activity [159]. Xanthone derivatives have also shown anticancer effects [160]. However, it is difficult for these molecules as well as other compounds in Figure 9 to distinguish between the anticancer effect caused by NKA inhibition and by modulations of other targets, e.g., the nuclear receptors.

Inhibitory constants of various NKA inhibitors from Figure 9 are given in Table 3.

### Table 3. Inhibitory constants (K<sub>i</sub>) of selected Na<sup>+</sup>/K<sup>+</sup>-ATPase inhibitors.

| Compound Name (Code) | Group of Compounds | K<sub>i</sub> or IC<sub>50</sub> [µM] | Isoform/Source | Ref. |
|----------------------|--------------------|-----------------|----------------|-----|
| Ouabain (1)          |                    | 0.09 ± 0.01     | Shark (rectal gland microsomes, α<sub>i</sub>) | [136] |
| Digoxin (2)          |                    | 0.13 ± 0.02     |                |     |
| Digitoxin (3)        |                    | 0.18 ± 0.01     |                |     |
| 4                    | Cardiac steroids   | 12.4 *          | Porcine cerebral cortex | [137] |
| Gitoxin (5)          |                    | 0.16 ± 0.04     | Shark (rectal gland microsomes, α<sub>i</sub>) | [136] |
| Evomonoside (6)      |                    | 0.11 ± 0.01     |                |     |
| Bufalin (7)          |                    | 0.13 ± 0.00     |                |     |
| Cinobufagin (8)      |                    | 0.68            | Pig kidney     | [152] |
| Gamabufotalin (9)    |                    | 0.16 ± 0.02     | Shark (rectal gland microsomes, α<sub>i</sub>) | [136] |
| 10                   | Sesquiterpenes     | 55.62 ± 0.41    | Porcine cerebral cortex | [154] |
| 11                   |                    | 212.0 ± 1.92    |                |     |
| 12                   |                    | 108.09 ± 2.01   |                |     |
| 13                   |                    | >494.22         |                |     |
| Panaxatriol (14)     | Triterpenes        | 1.09 ± 0.11     | Human Na<sup>+</sup>/K<sup>+</sup>-ATPase | [155] |
| 15                   |                    | 0.33 ± 0.03     |                |     |
| 16                   | Steroids           | 0.26 ± 0.03     |                |     |
| Istaroxime (17)      |                    | 0.11            |                |     |
| 18                   |                    | 0.02            | Dog kidney     | [158] |
| 19                   |                    | 0.02            |                |     |
| 3,4,5-trihydroxyxanthone (20) | Hydroxynanthones | 10.0            | Dog kidney     | [159] |
| 3,4,5,6-tetrahydroxyxanthone (21) | | 1.5            |                |     |

4. 4-(3R,3aR,5R,5aS,6bR,9aR,9aS,11S,12aS,14aR,14bS)-5,12a,14b-trihydroxy-3a,8,8-trimethyl-11-((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxyhexadecahydro-6H-cycloptenal[7]phenanthrol[4,4a][1,3]dioxin-3-yl)furan-2(5H)-one; 10. mixture of: a) 2-(2R,4aR,8aR)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-octahydroxanthophenalen-2-yl)prop-2-en-1-ol, b) 2-(2R,4aR,8aS)-4a-methyl-8-methylenedehydroxanthophenalen-2-yl)prop-2-en-1-ol, c) 2-(2R,4aR)-4a,8-dimethyl-1,2,3,4,4a,5,6,7-octahydroxanthophenalen-2-yl)prop-2-en-1-ol, 11. 2-(2R,4aR,8aR)-4a,8-dimethyl-1,2,3,4,4a,5,6,8a-octahydroxanthophenalen-2-yl)acrylaldehyde; 12. (R)-4-(1,2,2-trimethylcyclopentyl)phenyl)methanol; 13. (R)-1-methyl-4-(1,2,2-trimethylcyclopentyl)benzene; 15. (5R,6S,8R,10R,12R,13R,14R,17S)-6-(benzoxoxy)-12-hydroxy-4,4,8,10,14-pentamethyl-17-(R)-2,6,6-trimethyltetrahydro-2H-pyran-2-yl)hexadecahydro-3H-cycloptenal[7]phenanthrol-3-one; 16. methyl 3-(5S,3aR,4aR,6R,7R,9aR,9bR)-4-hydroxy-7-(2-hydroxypropan-2-yl)-6,9b-trimethyl-8-oxo-3-((R)-2,6,6-trimethyltetrahydro-2H-pyran-2-yl)dodecahydro-1H-cycloptenal[7]phenanthrol-6-yl)propanoate; 18. (5S,6E,8R,9S,10R,13S,15S)-3-(2-aminoethoxy)imino)-6-(methoxylimino)-10,13-dimethylhexadecahydro-17H-cycloptenal[7]phenanthrol-17-one, * p = 0.0002.
5.2. Endogenous NKA Modulators

In addition to exogenous modulators of NKA activity, there are also endogenous modulators. These compounds are present and synthesized directly in the human body and include cyclic adenosine monophosphate (cAMP). The cAMP molecule activates NKA via a signaling cascade that includes two independent pathways. The first one involves the activation of protein kinase A, while the second one activates the exchange of protein directly activated by cAMP (EPAC) 1 and 2. In both pathways, the next step is switching on the p21-activated kinase 4, which in turn triggers NKA [161]. Apart from cAMP, another endogenous NKA modulator is epinephrine (adrenaline), which induces the production of prostaglandin E2 (PGE2). Production of PGE2 ultimately leads to nitric oxide synthesis followed by the production of cyclic guanosine monophosphate and activation of protein kinase G, which results in NKA inhibition by its phosphorylation [162,163]. Besides, insulin can also regulate/activate NKA through activation of Src and extracellular signal-regulated kinases [164].

In Chapter 4, it has been shown that ROS regulates the activity of SrcK in an NKA signalosome; however, ROS also regulates the NKA pumping activity. Alharbi et al. [165] showed that ROS induced a decrease in the NKA activity, which led to apoptosis of canine cancer cells, and this effect was abrogated by pretreatment with an antioxidant N-acetylcysteine. The mechanism for this regulation of NKA activity lies in the S-glutathionylation of L-Cys residues, which leads to conformational change preventing ATP binding and thus reducing NKA activity [166,167]. However, Bibert et al. showed that the FXYD3 subunit can reverse this glutathionylation since its L-Cys residues are glutathionylated instead [168]. Another regulatory mechanism of NKA occurs during hypoxia and on the other hand, can be prevented upon reoxygenation. When cells lack oxygen, they tend to save energy by downregulating several ATP-consuming proteins, including NKA. This regulation is mediated by mitochondrial ROS and activation of protein kinase C-ζ, which leads to activation of clathrin-dependent endocytosis of NKA and degradation by the ubiquitin-conjugating system [169–171].

6. Conclusions

Cancer research has made a giant leap in recent decades owing to which, now, we not only better understand the cause of individual cancer diseases, but we also have better knowledge on systematic design of novel anticancer agents, which could have improved performance in terms of selectivity than the drugs currently used by clinicians. Recently, several research groups reported that one of cell essential enzymes, the sodium-potassium ATPase, could be a valid target in cancer treatment and that some of the natural compounds, from the group of CSs, are very potent inhibitors of NKA and when used at nontoxic low nanomolar concentrations, even selective for cancer cells. The selectivity of these compounds is probably caused by the binding of the α-subunit of NKA. However, further research needs to be done to better understand the anticancer mechanism of action of CSs. What is more, CS NKA inhibitors are very potent inducers of immunogenic cell death, by which they activate the immune system, based on which the therapy is far more efficient. Some of the CSs are used in clinical practice already from 1975 for the treatment of cardiac failure. Therefore, a possible repositioning of these compounds for other indications, such as cancer, is new hope for patients suffering from this severe disease. In addition, CSs could be used either alone or in a combination with other antineoplastic treatment methods. Thus, not only CSs, but also their molecular target, NKA, are more than valuable for further investigation. In conclusion, we hope that CSs and their semi-synthetic derivatives could be a new way for combating multidrug-resistant tumors.

Supplementary Materials: The following are available online, Table S1: A description of the listed gene products from STRING database; Table S2: A description of the listed gene products from STITCH database.
**Author Contributions:** All authors have contributed equally. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the project an internal grant from the budget for the implementation of the activities of the Institutional Plan of the UCT Prague in 2020 grant No. A1_FPBT_2020_004 and A2_FPBT_2020_015.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Acknowledgments:** The authors gratefully acknowledge the support by Martina Roeselová Foundation, Czech Republic, and L’Oreal-UNESCO for Women in Science 2019. The authors would like to also thank the IJMS journal for granting an APC waiver.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

- ABL1: Abelson tyrosine-protein kinase 1
- Akt: Protein kinase B
- ATP: Adenosine triphosphate
- BAD: Bcl2 associated agonist of cell death
- Bcl-XL: B-cell lymphoma-extra large
- cAMP: Cyclic adenosine monophosphate
- cGMP: Cyclic guanosine monophosphate
- CSs: Cardiac steroids
- EPAC: Exchange of protein directly activated by cAMP
- FAK: Focal adhesion kinase
- GTP: Guanosine triphosphate
- HIF-1α: Hypoxia-inducible factor 1 alpha
- IC50: Half maximal inhibitory concentration
- IP3: 1,4,5-Triphosphate
- K-Ras: Kirsten sarcoma virus protein
- MAPK: p38-mitogen-activated protein kinase
- mTOR: Mammalian target of rapamycin
- NKA: Sodium-potassium-ATPase
- p21cip1: Cyclin-dependent kinase inhibitor 1
- PI3K: Phosphatidylinositol 3-kinase
- PGE2: Prostaglandin E2
- ROS: Reactive oxygen species
- SERCA: Sarco-/endoplasmic reticular Ca2+-ATPase
- siRNA: Small interfering ribonucleic acid
- SrcK: Non-receptor tyrosine kinase
- VEGF: Vascular endothelial growth factor
- VRAC: Volume-regulated anion channels

**References**

1. Castagnetti, F.; Gugliotta, G.; Breccia, M.; Stagno, F.; Iurlo, A.; Albanò, F.; Abruzzese, E.; Martino, B.; Levato, L.; Intermesoli, T.; et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. *Leukemia* 2015, 29, 1823–1831. [CrossRef]

2. Zhang, H.; Berel, D.; Wang, Y.; Li, P.; Bhowmick, N.A.; Figlin, R.A.; Kim, H.L. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models. *PLoS ONE* 2013, 8, e54918. [CrossRef]

3. FDA. Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-pi3k-inhibitor-breast-cancer (accessed on 13 October 2020).

4. McCarthy, M.J.; Pagba, C.V.; Prakash, P.; Najji, A.K.; van der Hoeven, D.; Liang, H.; Gupta, A.K.; Zhou, Y.; Cho, K.J.; Hancock, J.F. Discovery of high-affinity noncovalent allosteric KRAS inhibitors that disrupt effector binding. *ACS Omega* 2019, 4, 2921–2930. [CrossRef]

5. Guimarães, I.S.; Daltoé, R.D.; Herlinger, A.L.; Madeira, K.P.; Ladislau, T.; Valadão, J.C.; Lyra, P.C.M., Jr.; Teixeira, S.F.; Amorim, G.M.; dos Santos, D.Z.; et al. Conventional cancer treatment. In *Cancer Treatment—Conventional and Innovative Approaches*; Rangel, L., Ed.; IntechOpen: London, UK, 2013; pp. 3–35. [CrossRef]
6. Pucci, C.; Martinelli, C.; Ciofani, G. Innovative approaches for cancer treatment: Current perspectives and new challenges. *Eancermedicalsience* 2019, 13, 961. [CrossRef] [PubMed]

7. Castillo, J.P.; De Giorgis, D.; Basilio, D.; Gadsby, D.C.; Rosenthal, J.J.C.; Latorre, R.; Holmgren, M.; Bezanilla, F. Energy landscape of the reactions governing the Na⁺-diffusely occluded state of the Na⁺/K⁺-ATPase in the giant axon of the houndshldt squid. *Proc. Natl. Acad. Sci. USA* 2011, 108, 20556–20561. [CrossRef]

8. Blom, H.; Bernheim, K.; Brismara, H. Sodium pump organization in dendritic spines. *Neurophotonics* 2016, 3, 041803. [CrossRef] [PubMed]

9. Ferrer-Martinez, A.; Casado, F.J.; Felipe, A.; Pastor-Anglada, M. Regulation of Na⁺,K⁺-ATPase and the Na⁺/K⁺/Cl⁻ co-transporter in the renal epithelial cell line NBL-1 ender osmotic stress. *Biochem. J.* 1996, 319, 337–342. [CrossRef] [PubMed]

10. Tang, C.H.; Wu, W.Y.; Tsai, S.C.; Yoshinaga, T.; Lee, I.H. Elevated Na⁺ responses and its potential role in triggering ion reabsorption in kidneys for homeostasis of marine euryhaline milkfish (Chanos chanos) when acclimated to hypotonic fresh water. *J. Comp. Physiol. B* 2010, 180, 813–824. [CrossRef]

11. Wong, M.K.S.; Pipil, S.; Ozaki, H.; Suzuki, Y.; Iwasaki, W.; Takei, Y. Flexible selection of diversified Na⁺/K⁺-ATPase α-subunit isoforms for osmoregulation in teleosts. *Zool. Lett.* 2016, 2, 15. [CrossRef]

12. Tian, J.; Cai, T.; Yuan, Z.; Wang, H.; Liu, L.; Haas, M.; Maksimova, E.; Huang, X.Y.; Xie, Z.J. Binding of Src to Na⁺/K⁺-ATPase forms a functional signaling complex. *Mol. Biol. Cell* 2006, 17, 317–326. [CrossRef]

13. Aydemir-Koksoy, A.; Abramowitz, J.; Allen, J.C. Ouabain-induced signaling and vascular smooth muscle cell proliferation. *Am. J. Physiol. Cell Physiol.* 2007, 292, C15–C22. [CrossRef] [PubMed]

14. Chen, L.; Jiang, P.; Li, J.; Xie, Z.; Xu, Y.; Qu, W.; Feng, F.; Liu, W. Periplocin promotes wound healing through the activation of Src/ERK and PI3K/Akt pathways mediated by Na/K-ATPase. *PLoS ONE* 2015, 10, e0128204. [CrossRef] [PubMed]

15. Prassas, I.; Karagiannis, G.S.; Batruch, I.; Dimitromanolakis, A.; Datti, A.; Diamandis, E.P. Digitoxin-induced cytotoxicity in cancer cells is mediated through distinct kinase and interferon signaling networks. *Mol. Cancer Ther.* 2011, 10, 2083–2093. [CrossRef]

16. Khajah, M.A.; Mathew, P.M.; Luqmani, Y.A. Na⁺/K⁺-ATPase activity promotes invasion of endocrine resistant breast cancer cells. *PloS ONE* 2018, 13, e0193779. [CrossRef]

17. Edwards, I.A.; Bruce, G.; Lawrenson, C.; Howe, L.; Clapcote, S.J.; Deuchars, J.; Deuchars, S.A.; Deuchars, J. Na⁺/K⁺-ATPase α1 and α3 isoforms are differentially expressed in α- and γ-motoneurons. *J. Neurosci.* 2013, 33, 9913–9919. [CrossRef]

18. Radzyukevich, T.L.; Neumann, J.C.; Rindler, T.N.; Oshiro, N.; Goldhamer, D.J.; Lingrel, J.B.; Heiny, J.A. Tissue-specific role of the Na⁺,K⁺-ATPase and the Na⁺/K⁺/Cl⁻ co-transporter in the renal epithelial cell line NBL-1 ender osmotic stress. *Biochem. J.* 1996, 319, 337–342. [CrossRef] [PubMed]

19. Sanchez, G.; Nguyen, A.N.T.; Timmerberg, B.; Tash, J.S.; Blanco, G. The Na,K-ATPase alpha4 isoform from humans has distinct enzymatic properties and is important for sperm motility. *Mol. Hum. Reprod.* 2006, 12, 565–576. [CrossRef] [PubMed]

20. Hundler, K.; Marette, A.; Ramal, T.; Liu, Z.; Klip, A. Expression of beta subunit isoforms of the Na⁺,K⁺-ATPase is muscle type-specific. *FEBS Lett.* 1993, 328, 253–258. [CrossRef]

21. Arystarkhova, E.; Sweedner, K.J. Tissue-specific expression of the Na⁺,K⁺-ATPase beta3 subunit. The presence of beta3 in lung and liver addresses the problem of the missing subunit. *J. Biol. Chem.* 1997, 272, 22405–22408. [CrossRef]

22. PDB. Available online: https://www.rcsb.org/structure/3A3Y (accessed on 2 February 2021).

23. Pucci, C.; Martinelli, C.; Ciofani, G. Innovative approaches for cancer treatment: Current perspectives and new challenges. *Eancermedicalsience* 2019, 13, 961. [CrossRef] [PubMed]

24. Mort, J.P.; Pedersen, B.P.; Tounstrup-Jensen, M.S.; Sørensen, T.L.; Petersen, J.; Andersen, J.P.; Vilsen, B.; Nissen, P. Crystal structure of the sodium-potassium pump. *Nature* 2007, 450, 1043–1049. [CrossRef] [PubMed]

25. Hillers, F.; Kopec, W.; Isaksen, T.J.; Holm, T.H.; Lykke-Hartmann, K.; Nissen, P.; Khandelia, H.; Poulsen, H. Tuning of the Na,K-ATPase by the beta subunit. *Sci. Rep.* 2016, 6, 20442. [CrossRef]

26. Rajasekaran, S.A.; Gopal, J.; Willis, D.; Espineda, C.; Twiss, J.L.; Rajasekaran, A.K. Na,K-ATPase β1-subunit increases the translation efficiency of the α1-Subunit in MSV-MDCK cells. *Mol. Biol. Cell* 2004, 15, 3005–3508. [CrossRef]

27. Miller, R.P.; Farley, R.A. All three potential N-glycosylation sites of the dog kidney (Na⁺ + K⁺)-ATPase beta-subunit contain oligosaccharide. *Biochim. Biophys. Acta* 1988, 954, 50–57. [CrossRef]

28. Beggah, A.T.; Jaunin, P.; Geering, K. Role of glycosylation and disulfide bond formation in the beta subunit in the folding and functional expression of Na⁺/K⁺-ATPase. *J. Biol. Chem.* 1997, 272, 10318–10326. [CrossRef] [PubMed]

29. Kanagawa, M.; Matsumoto, K.; Iwasaki, N.; Hayashi, Y.; Yamaguchi, Y. Structural analysis of N-glycans attached to pig kidney Na⁺/K⁺-ATPase. *J. Glyc. Lip.* 2013, 55, 005. [CrossRef]

30. Tokhtaeva, E.; Munson, K.; Sachs, G.; Vagin, T. O.Glycan-dependent quality control of the Na,K-ATPase β2 subunit. *Biochemistry* 2010, 49, 3116–3128. [CrossRef]

31. Béguin, P.; Hasler, U.; Staub, O.; Geering, K. Endoplasmic reticulum quality control of oligomeric membrane proteins: Topogenic determinants involved in the degradation of the unassembled Na,K-ATPase alpha subunit and in its stabilization by beta subunit assembly. *Mol. Biol. Cell.* 2000, 11, 1657–1672. [CrossRef]

32. Tokhtaeva, E.; Sachs, G.; Vagin, O. Assembly with the Na,K-ATPase α1 subunit is required for export of β1 and β2 subunits from the endoplasmic reticulum. *Biochemistry* 2008, 47, 11421–11431. [CrossRef]

33. Lian, W.N.; Wu, T.W.; Dao, R.L.; Chen, Y.J.; Lin, C.H. Deglycosylation of Na⁺/K⁺-ATPase causes the basolateral protein to undergo apical targeting in polarized hepatic cells. *J. Cell Sci.* 2006, 119, 11–22. [CrossRef] [PubMed]
34. Vagin, O.; Tokhtaeva, E.; Sachs, G. The role of the β1 subunit of the Na,K-ATPase and its glycosylation in cell-cell adhesion. J. Cell. Biol. 2006, 201, 39573–39587. [CrossRef]

35. Wang, P.J.; Lin, C.H.; Hwang, H.H.; Lee, T.H. Branchial FXYD protein expression in response to salinity change and its interaction with Na+/K+ -ATPase of the euryhaline teleost Tetraodon nigroviridis. J. Exp. Biol. 2008, 211, 3750–3758. [CrossRef]

36. Wang, L.J.; Li, Q.J.; Le, Y.; Ouyang, H.Y.; He, M.K.; Yu, Z.S.; Zhang, Y.F.; Shi, M. Prognostic significance of sodium-potassium ATPase regulator, FXYD3, in human hepatocellular. Carcinoma Oncol. Lett. 2018, 15, 3024–3030. [CrossRef]

37. Widgren, E.; Örnesjö, S.; Arbman, G.; Kayed, H.; Zentgraf, H.; Kleeff, J.; Zhang, H.; Sun, X.-F. Expression of FXYD3 protein in relation to biological and clinicopathological variables in colorectal cancers. Chemotherapy 2009, 55, 407–413. [CrossRef] [PubMed]

38. Zhang, Z.; Pang, S.T.; Kasper, K.A.; Luan, C.; Wondergem, B.; Lin, F.; Chuang, C.K.; Teh, B.T.; Yang, X.J. FXYD3: A promising biomarker for urothelial carcinoma. Biomark Insights 2011, 6, 17–26. [CrossRef]

39. Herrmann, P.; Aronica, S.M. Estrogen and tamoxifen up-regulate FXYD3 on breast cancer cells: Assessing the differential roles of ER α and ZEB1. Springerplus 2015, 4, 245. [CrossRef] [PubMed]

40. Kayed, H.; Kleeff, J.; Kolb, A.; Ketterer, K.; Keleg, S.; Giese, T.; Penzel, R.; Zentgraf, H.; Büchler, M.W.; et al. FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. Int. J. Cancer 2006, 118, 43–54. [CrossRef] [PubMed]

41. Uniprot. Available online: https://www.uniprot.org/uniprot/O00168 (accessed on 6 October 2020).

42. Uniprot. Available online: https://www.uniprot.org/uniprot/P54710 (accessed on 6 October 2020).

43. Uniprot. Available online: https://www.uniprot.org/uniprot/P59646 (accessed on 6 October 2020).

44. Uniprot. Available online: https://www.uniprot.org/uniprot/Q14802-5 (accessed on 6 October 2020).

45. Uniprot. Available online: https://www.uniprot.org/uniprot/P58549 (accessed on 6 October 2020).

46. Uniprot. Available online: https://www.uniprot.org/uniprot/Q96DB9 (accessed on 6 October 2020).

47. Uniprot. Available online: https://www.uniprot.org/uniprot/P05023/expression (accessed on 6 October 2020).

48. Uniprot. Available online: https://www.uniprot.org/uniprot/924564/expression (accessed on 6 October 2020).

49. Uniprot. Available online: https://www.uniprot.org/uniprot/Q91003 (accessed on 6 October 2020).

50. Uniprot. Available online: https://www.uniprot.org/uniprot/P65436 (accessed on 6 October 2020).

51. Proteomics DB. Available online: https://www.proteomicsdb.org/proteomicsdb/#protein/proteinDetails/80311/expression (accessed on 6 October 2020).

52. Proteomics DB. Available online: https://www.proteomicsdb.org/proteomicsdb/#protein/proteinDetails/56274/expression (accessed on 6 October 2020).

53. Proteomics DB. Available online: https://www.proteomicsdb.org/proteomicsdb/#protein/proteinDetails/52946/expression (accessed on 6 October 2020).

54. Proteomics DB. Available online: https://www.proteomicsdb.org/proteomicsdb/#protein/proteinDetails/56699/expression (accessed on 6 October 2020).

55. Proteomics DB. Available online: https://www.proteomicsdb.org/proteomicsdb/#protein/proteinDetails/51770/expression (accessed on 6 October 2020).

56. Proteomics DB. Available online: https://www.proteomicsdb.org/proteomicsdb/#protein/proteinDetails/53052/expression (accessed on 6 October 2020).

57. Proteomics DB. Available online: https://www.proteomicsdb.org/proteomicsdb/#protein/proteinDetails/505023/expression (accessed on 6 October 2020).

58. Proteomics DB. Available online: https://www.proteomicsdb.org/proteomicsdb/#protein/proteinDetails/60188/expression (accessed on 6 October 2020).

59. Schwanhäusser, B.; Busse, D.; Li, N.; Dittmar, G.; Schuchhardt, J.; Wolf, J.; Chen, W.; Selbach, M. Global quantification of mammalian gene expression control. Nature 2011, 473, 337–342. [CrossRef]

60. Mishra, N.K.; Peleg, Y.; Cirri, E.; Belogus, T.; Lifshitz, Y.; Voelker, D.R.; Apell, H.J.; Garty, H.; Karlish, S.J.D. FXYD proteins stabilize Na,K-ATPase: Amplification of specific phosphatidylserine-protein interactions. J. Biol. Chem. 2011, 286, 9699–9712. [CrossRef] [PubMed]

61. Tokhtaeva, E.; Sun, H.; Deiss-Yehiely, N.; Wen, Y.; Soni, P.N.; Gabrielli, N.M.; Marcus, E.A.; Ridge, K.M.; Sachs, G.; Vazquez-Levin, M.; et al. The O-glycosylated ectodomain of FXYD5 impairs adhesion by disrupting cell-cell trans-dimerization of Na,K-ATPase β1 subunits. J. Cell Sci. 2016, 129, 2394–2406. [CrossRef] [PubMed]

62. Cirri, E.; Katz, A.; Mishra, N.K.; Belogus, T.; Lifshitz, Y.; Garty, H.; Karlish, S.J.D.; Apell, H.J. Phospholemman (FXYD1) raises the affinity of the human α1β1 isoform of Na,K-ATPase for Na ions. Biochemistry 2011, 50, 3736–3748. [CrossRef] [PubMed]

63. Despa, S.; Bossuyt, J.; Han, F.; Ginsburg, K.S.; Jia, L.G.; Kutchai, H.; Tucker, A.L.; Bers, D.M. Phospholemman-phosphorylation mediates the β-adrenergic effects on Na/K pump function in cardiac myocytes. Circ. Res. 2005, 97, 252–259. [CrossRef]

64. Silva, E.C.C.; Masui, D.C.; Furriel, R.P.; McNamara, J.C.; Barrabina, H.; Scobano, H.M.; Perales, J.; Teixeira-Ferreira, A.; Leone, F.A.; Fontes, C.F.L. Identification of a crab gill FXYD2 protein and regulation of crab microsomal Na,K-ATPase activity by mammalian FXYD2 peptide. Biochim. Biophys. Acta-Biomenetr. 2012, 1818, 2588–2597. [CrossRef] [PubMed]
91. Haas, M.; Wang, H.; Tian, J.; Xie, Z. Src-mediated inter-receptor cross-talk between the Na\(^+\)/K\(^+-\)ATPase and the epidermal growth factor receptor relays the signal from ouabain to mitogen-activated protein kinases. *J. Biol. Chem.* 2002, 277, 18694–18702. [CrossRef] [PubMed]

92. Nguyen, A.N.T.; Jansson, K.; Sánchez, G.; Sharma, M.; Reif, G.A.; Blanco, G. Ouabain activates the Na-K-ATPase signalosome to induce autosomal dominant polycystic kidney disease cell proliferation. *Am. J. Physiol. Renal. Physiol.* 2011, 301, F897–F906. [CrossRef]

93. Tverskoi, A.M.; Sidorenko, S.V.; Klimanova, E.A.; Akimova, O.A.; Smolyaninova, L.V.; Lopina, O.D.; Orlov, S.N. Effects of ouabain on proliferation of human endothelial cells correlate with Na-K-ATPase activity and intracellular ratio of Na and K. *Biochemistry* 2016, 81, 876–883. [CrossRef]

94. Banerjee, G.M.; Cui, X.; Li, Z.; Yu, H.; Cai, L.; Jia, X.; He, D.; Wang, C.; Gao, T.; Xie, Z. Na-K-ATPase Y260 phosphorylation–mediated Src regulation in control of aerobic glycolysis and tumor. *Sci. Rep.* 2018, 8, 12322. [CrossRef] [PubMed]

95. Li, Z.; Zhang, Z.; Xie, J.; Li, X.; Tian, J.; Cai, T.; Cui, H.; Ding, H.; Shapiro, J.I.; Xie, Z. Na/K-ATPase mimetic pNaKtide peptide inhibits the growth of human cancer cells. *J. Biol. Chem.* 2011, 286, 32394–32403. [CrossRef] [PubMed]

96. Sodhi, K.; Nichols, A.; Mallick, A.; Klug, R.L.; Liu, J.; Wang, X.; Srikantnhan, K.; Goguet-Rubio, P.; Nawab, A.; Pratt, R.; et al. The Na/K-ATPase oxidant amplification loop regulates aging. *Sci. Rep.* 2018, 8, 9721. [CrossRef] [PubMed]

97. Sodhi, K.; Maxwell, K.; Yan, Y.; Liu, J.; Chaudhry, M.; Xie, Z.; Abraham, N.G.; Shapiro, J.I. pNaKtide inhibits Na-K-ATPase reactive oxygen species amplification and attenuates adipogenesis. *Sci. Adv.* 2015, 1, e150781. [CrossRef] [PubMed]

98. Sodhi, K.; Srikantnhan, K.; Goguet-Rubio, P.; Nichols, A.; Mallick, A.; Nawab, A.; Martin, R.; Shah, P.T.; Chaudhry, M.; Sigdel, S.; et al. pNaKtide attenuates steatohepatitis and atherosclerosis by blocking Na/K-ATPase/ROS amplification in C57Bl/6 and ApoE knockout mice fed a western diet. *Sci. Rep.* 2017, 7, 193. [CrossRef]

99. Wang, Y.; Ye, Q.; Liu, C.; Xie, J.X.; Yan, Y.; Lai, F.; Duan, Q.; Li, X.; Tian, J.; Xie, Z. Involvement of Na/K-ATPase in hydrogen peroxide-induced activation of the Src/ERK pathway in LLC-PK1 cells. *Free Radic. Biol. Med.* 2014, 71, 415–426. [CrossRef]

100. Yan, Y.; Shapiro, A.P.; Mopidevi, B.R.; Chaudhry, M.A.; Maxwell, K.; Haller, S.T.; Drummond, C.A.; Kennedy, D.J.; Tian, J.; Malhotra, D.; et al. Protein carbonylation of an amino acid residue of the Na-K-ATPase α1 subunit determines Na-K-ATPase signaling and sodium transport in renal proximal tubular cells. *J. Am. Heal Heart Assoc.* 2016, 5, e003675. [CrossRef]

101. Yan, Y.; Shapiro, A.P.; Haller, S.; Katragadda, V.; Liu, J.; Tian, J.; Basrur, V.; Malhotra, D.; Xie, Z.; Abraham, N.G.; et al. Involvement of reactive oxygen species in a feed-forward mechanism of Na/K-ATPase-mediated signaling transduction. *J. Biol. Chem.* 2013, 288, 34249–34258. [CrossRef]

102. Yu, H.; Cui, X.; Zhang, J.; Xie, J.X.; Banerjee, M.; Pierre, S.V.; Xie, Z. Heterogeneity of signal transduction by Na-K-ATPase α-isomers: Role of Src interaction. *Am. J. Physiol. Cell Physiol.* 2018, 314, C202–C210. [CrossRef]

103. Miyakawa-Naito, A.; Uhlen, P.; Lal, M.; Aizman, O.; Mikoshiba, K.; Brismar, H.; Zelenin, S.; Aperia, A. Cell signaling microdomain with Na,K-ATPase and inositol 1,4,5-trisphosphate receptor generates calcium oscillations. *J. Biol. Chem.* 2003, 278, 50355–50361. [CrossRef]

104. Yuan, Z.; Cai, T.; Tian, J.; Ivanov, A.V.; Giovannucci, D.R.; Xie, Z. Na/K-ATPase tethers phospholipase C and IP3 receptor into a calcium- regulatory complex. *Mol. Cell 2005, 16, 4034–4045. [CrossRef]

105. Burlaka, I.; Liu, X.L.; Rebetz, J.; Arvidsson, J.; Yang, L.; Brismar, K.; Karpm, D.; Aperia, A. Ouabain protects against shiga toxin–triggered apoptosis by reversing the imbalance between Bax and Bcl-xL. *Mol. Biol. Cell.* 2005, 16, 4034–4045. [CrossRef]

106. Pan, L.; Zhang, Y.; Zhao, W.; Zhou, X.; Wang, C.; Deng, F. The cardiac glycoside oleandrin induces apoptosis in human colon cancer cells via the mitochondrial pathway. *Cancer Chemoth. Pharmacol.* 2017, 80, 91–100. [CrossRef] [PubMed]
114. Kometiani, P.; Liu, L.; Askari, A. Digitalis-induced signaling by Na+/K+-ATPase in human breast cancer cells. *Mol. Pharmacol.* 2005, 67, 929–936. [CrossRef] [PubMed]

115. Lin, S.Y.; Chang, H.H.; Lai, Y.H.; Lin, C.H.; Chen, M.H.; Chang, G.C.; Tsai, M.F.; Chen, J.W. Digoxin suppresses tumor malignancy through inhibiting multiple Src-related signaling pathways in non-small cell lung cancer. *PLoS ONE* 2015, 10, e0123305. [CrossRef]

116. Shin, H.K.; Ryu, B.J.; Choi, S.W.; Kim, S.H.; Le, K. Inactivation of Src-to-erlin pathway: A possible mechanism in the ouabain-mediated inhibition of A549 cell growth. *Biomed. Res. Int.* 2015, 2015, 537136. [CrossRef]

117. Pongkrakhanon, V.; Chunhacha, P.; Chanvorachote, P. Ouabain suppresses the migratory behavior of lung cancer cells. *PLoS ONE* 2013, 8, e66823. [CrossRef]

118. Kornberg, L.J.; Shaw, L.C.; Spoerri, P.E.; Caballero, S.; Grant, M.B. Focal adhesion kinase overexpression induces enhanced pathological retinal angiogenesis. *Invest. Ophthalmol. Vis. Sci.* 2004, 45, 4463–4469. [CrossRef]

119. Cabrita, M.A.; Jones, L.M.; Quizi, J.L.; Sabourin, L.A.; McKay, B.C.; Addison, C.L. Focal adhesion kinase inhibitors are potent anti-angiogenic agents. *Mol. Oncol.* 2011, 5, 517–526. [CrossRef]

120. Pedrosa, A.R.; Bodrug, N.; Gomez-Escudero, J.; Carter, E.P.; Reynolds, L.E.; Georgiou, P.N.; Fernandez, I.; Lees, D.M.; Kostourou, V.; Alexeopoulou, A.N.; et al. Tumor angiogenesis is differentially regulated by phosphorylation of endothelial cell focal adhesion kinase tyrosines-397 and -861. *Cancer Res.* 2019, 79, 4371–4386. [CrossRef]

121. Trenti, A.; Zulato, E.; Pasqualini, L.; Indraccolo, S.; Bolego, C.; Trevisi, L. Therapeutic concentrations of digitoxin inhibit endothelial focal adhesion kinase adhesion and induced neovascularization by different growth factors. *Br. J. Pharmacol.* 2017, 174, 3094–3106. [CrossRef]

122. Pouysségur, J.; Dayan, F.; Mazure, N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. *Nature* 2006, 441, 437–443. [CrossRef]

123. Yamakawa, M.; Liu, L.X.; Date, T.; Belanger, A.J.; Vincent, K.A.; Akita, G.Y.; Kuriyama, T.; Cheng, S.H.; Gregory, R.J.; Jiang, C. Oncotarget 2017, 8, 40233–40245. [CrossRef] [PubMed]

124. Yang, X.S.; Xu, Z.W.; Yi, T.L.; Xu, R.C.; Li, J.; Zhang, W.B.; Zhang, S.; Sun, H.T.; Yu, Z.Q.; Xu, H.X.; et al. Ouabain suppresses the growth and migration abilities of glioma U-87MG cells through inhibiting the Akt/mTOR signaling pathway and downregulating the expression of HIF-1α. *Mol. Med. Rep.* 2018, 17, 5595–5600. [CrossRef]

125. Fujii, T.; Shimizu, T.; Yamamoto, S.; Funayama, K.; Fujita, K.; Tabuchi, Y.; Ikari, A.; Takeshima, H.; Sakai, H. Crossstalk between Na⁺/K⁺-ATPase and a volume-regulated anion channel in membrane microdomains of human cancer cells. *Biochim. Biophys. Acta-Mol. Basis Dis.* 2018, 1864, 3792–3804. [CrossRef]

126. STRING. Available online: http://string.embl.de/ (accessed on 14 August 2020).

127. Fujiwara, J.; Dayan, F.; Mazure, N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. *Nature* 2006, 441, 437–443. [CrossRef]

128. Yamakawa, M.; Liu, L.X.; Date, T.; Belanger, A.J.; Vincent, K.A.; Akita, G.Y.; Kuriyama, T.; Cheng, S.H.; Gregory, R.J.; Jiang, C. Oncotarget 2017, 8, 40233–40245. [CrossRef] [PubMed]

129. Yang, X.S.; Xu, Z.W.; Yi, T.L.; Xu, R.C.; Li, J.; Zhang, W.B.; Zhang, S.; Sun, H.T.; Yu, Z.Q.; Xu, H.X.; et al. Ouabain suppresses the growth and migration abilities of glioma U-87MG cells through inhibiting the Akt/mTOR signaling pathway and downregulating the expression of HIF-1α. *Mol. Med. Rep.* 2018, 17, 5595–5600. [CrossRef]

130. Fujii, T.; Shimizu, T.; Yamamoto, S.; Funayama, K.; Fujita, K.; Tabuchi, Y.; Ikari, A.; Takeshima, H.; Sakai, H. Crossstalk between Na⁺/K⁺-ATPase and a volume-regulated anion channel in membrane microdomains of human cancer cells. *Biochim. Biophys. Acta-Mol. Basis Dis.* 2018, 1864, 3792–3804. [CrossRef]

131. Dalla, S.; Swarts, H.G.; Koenderink, J.B.; Dobler, S. Amino acid substitutions of Na⁺,K⁺-ATPase conferring decreased sensitivity to cardenolides in insects compared to mammals insect. *Biochem. Mol. Biol.* 2013, 43, 1109–1115. [CrossRef]

132. STITCH. Available online: https://stitch-db.org/ (accessed on 18 August 2020).

133. Cornelius, F.; Kanai, R.; Toyoshima, C. A structural view on the functional importance of the sugar moiety and steroid hydroxyls of cardiotonic steroids in binding to Na⁺,K⁺-ATPase. *J. Biol. Chem.* 2013, 288, 6602–6616. [CrossRef]

134. Maggusao, A.N.; Omolloh, G.; Johnson, J.; Gascón, J.; Peczuh, M.W.; Fenteany, G. Cardiac glycoside activities link Na⁺+K⁺-ATPase ion-transport to breast cancer cell migration via correlative SAR. *ACS Chem. Biol.* 2015, 10, 561–569. [CrossRef]

135. Manunta, P.; Hamilton, B.P.; Hamlyn, J.M. Structure-function relationships for the hypotensive efficacy of ouabain: Role of the sugar and lactone ring. *Hypertension* 2001, 37, 472–477. [CrossRef]

136. Pouysségur, J.; Dayan, F.; Mazure, N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. *Nature* 2006, 441, 437–443. [CrossRef]

137. Fujiwara, J.; Dayan, F.; Mazure, N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. *Nature* 2006, 441, 437–443. [CrossRef]
140. Rocha, S.C.; Pessoa, M.T.C.; Neves, L.D.R.; Alves, S.L.G.; Silva, L.M.; Santos, H.L.; Oliveira, S.M.F.; Taranto, A.G.; Comar, M.; Gomes, I.V.; et al. 21-Benzylidene digoxin: A proapoptotic cardenolidine of cancer cells that up-regulates Na,K-ATPase and epithelial tight junctions. *PloS ONE* 2019, 9, e018876. [CrossRef]

141. Alves, S.L.G.; Paixão, N.; Ferreira, L.G.R.; Santos, F.R.S.; Neves, L.D.R.; Oliveira, G.C.; Cortes, V.F.; Salomé, K.S.; Barison, A.; Santos, F.V.; et al. 9γ-Benzylidene digoxin derivatives synthesis and molecular modeling: Evaluation of anticancer and the Na,K-ATPase activity effect. *Bioorg. Med. Chem.* 2015, 23, 4397–4404. [CrossRef] [PubMed]

142. Pessaôa, M.T.C.; Alves, S.L.G.; Taranto, A.G.; Villar, J.A.F.P.; Blanco, G.; Barbosa, L.A. Selectivity analyses of γ-benzylidene digoxin derivatives to different Na,K-ATPase α isoforms: A molecular docking approach. *J. Enzyme Inhib. Med. Chem.* 2018, 33, 85–97. [CrossRef] [PubMed]

143. Syeda, S.S.; Sánchez, G.; Hong, K.H.; Hawkison, J.E.; Georg, G.I.; Blanco, G. Design, synthesis, and in vitro and in vivo evaluation of ouabain analogues as potent and selective Na,K-ATPase α4 isoform inhibitors for male contraception. *J. Med. Chem.* 2018, 61, 1800–1820. [CrossRef]

144. Iyer, A.K.V.; Zhou, M.; Azad, N.; Elbaz, H.; Wang, L.; Rogalsky, D.K.; Rojanasakul, Y.; O’Doherty, G.A.; Langenhan, J.M. A direct comparison of the anticancer activities of digitoxin MeON-neoglycosides and O-glycosides. *ACS Med. Chem. Lett.* 2010, 1, 326–330. [CrossRef]

145. Elbaz, H.A.; Stueckle, T.A.; Wang, H.Y.L.; O’Doherty, G.A.; Lowry, D.T.; Sargent, L.M.; Wang, L.; Dinu, C.Z.; Rojanasakul, Y. Digitoxin and a synthetic monosaccharide analog inhibit cell viability in lung cancer cells. A review to explore the mechanism of actions. *Molecules* 2020, 25, 3969. [CrossRef] [PubMed]

146. Katz, A.; Lifshitz, Y.; Bab-Dinitz, E.; Kapri-Pardes, E.; Goldshleger, R.; Tal, D.M.; Karlish, S.J.D. Selectivity of digitalis glycosides for isoforms of human Na,K-ATPase. *J. Biol. Chem.* 2008, 285, 19582–19592. [CrossRef]

147. Reddy, D.; Kumavath, R.; Barh, D.; Azevedo, V.; Ghosh, P. Anticancer and antiviral properties of cardiac glycosides: A review to

148. Moussawi, L.E.; Mohamed, C.; Kreydiyyeh, S.I. Epinephrine modulates Na⁺/K⁺ ATPase activity in Caco-2 cells via Src, p38MAPK, ERK and PGE2. *PLoS ONE* 2018, 13, e0193139. [CrossRef]

149. Moussawi, L.E.; Mohamed, C.; Kreydiyyeh, S. The epinephrine-induced PGE2 reduces Na⁺/K⁺ ATPase activity in Caco-2 cells via PKC, NF-xB and NO. *PLoS ONE* 2019, 14, e0220987. [CrossRef]
164. Shahidullah, M.; Mandal, A.; Delamere, N.A. Src family kinase links insulin signaling to short term regulation of Na,K-ATPase in nonpigmented ciliary epithelium. *J. Cell. Physiol.* 2017, 232, 1489–1500. [CrossRef]

165. Alharbi, Y.; Kapur, A.; Felder, M.; Barroilhet, L.; Stein, T.; Pattnaik, B.R.; Patankar, M.S. Plumbagin-induced oxidative stress leads to inhibition of Na\(^+\)/K\(^-\)-ATPase (NKA) in canine cancer cells. *Sci. Rep.* 2019, 9, 11471. [CrossRef]

166. Petrushanko, I.Y.; Yakushev, S.; Mitkevich, V.A.; Kamanina, Y.V.; Ziganshin, R.H.; Meng, X.; Anashkina, A.A.; Makhro, A.; Lopina, O.D.; Gassmann, M.; et al. S-glutathionylation of the Na,K-ATPase catalytic α subunit is a determinant of the enzyme redox sensitivity. *J. Biol. Chem.* 2012, 287, 32195–32205. [CrossRef] [PubMed]

167. Juel, C. Oxidative stress (glutathionylation) and Na,K-ATPase activity in rat skeletal muscle. *PLoS ONE* 2014, 13, e110514. [CrossRef] [PubMed]

168. Bibert, S.; Liu, C.C.; Figtree, G.A.; Garcia, A.; Hamilton, E.J.; Marassi, F.M.; Sweadner, K.J.; Cornelius, F.; Geering, K.; Rasmussen, H.H. FXYD proteins reverse inhibition of the Na\(^+\)-K\(^-\) pump mediated by glutathionylation of its beta1 subunit. *J. Biol. Chem.* 2011, 286, 18562–18572. [CrossRef] [PubMed]

169. Dada, L.A.; Chandel, N.S.; Ridge, K.M.; Pedemonte, C.; Bertorello, A.M.; Sznajder, J.I. Hypoxia-induced endocytosis of Na,K-ATPase in alveolar epithelial cells is mediated by mitochondrial reactive oxygen species and PKC-zeta. *J. Clin. Investig.* 2003, 111, 1057–1064. [CrossRef] [PubMed]

170. Comellas, A.P.; Dada, L.A.; Lecuona, E.; Pesce, L.M.; Chandel, N.S.; Quesada, N.; Budinger, G.R.S.; Strous, G.J.; Ciechanover, A.; Sznajder, J.I. Hypoxia-mediated degradation of Na,K-ATPase via mitochondrial reactive oxygen species and the ubiquitin-conjugating system. *Circ. Res.* 2006, 98, 1314–1322. [CrossRef] [PubMed]

171. Chen, Z.; Krmar, R.T.; Dada, L.; Efendiev, R.; Leibiger, I.B.; Pedemonte, C.H.; Katz, A.I.; Sznajder, J.I.; Bertorello, A.M. Phosphorylation of adaptor protein-2 mu2 is essential for Na\(^+\),K\(^-\)-ATPase endocytosis in response to either G protein-coupled receptor or reactive oxygen species. *Am. J. Respir. Cell Mol. Biol.* 2006, 35, 127–132. [CrossRef] [PubMed]